Compare CW & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CW | PODD |
|---|---|---|
| Founded | 1929 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.3B | 21.0B |
| IPO Year | N/A | 2007 |
| Metric | CW | PODD |
|---|---|---|
| Price | $659.69 | $264.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 19 |
| Target Price | ★ $582.50 | $367.32 |
| AVG Volume (30 Days) | 209.5K | ★ 727.2K |
| Earning Date | 02-11-2026 | 02-18-2026 |
| Dividend Yield | ★ 0.15% | N/A |
| EPS Growth | ★ 15.99 | N/A |
| EPS | ★ 12.27 | 3.45 |
| Revenue | ★ $3,375,704,000.00 | $2,521,800,000.00 |
| Revenue This Year | $13.58 | $32.55 |
| Revenue Next Year | $7.28 | $20.47 |
| P/E Ratio | ★ $52.93 | $78.62 |
| Revenue Growth | 9.51 | ★ 27.11 |
| 52 Week Low | $266.88 | $230.05 |
| 52 Week High | $669.98 | $354.88 |
| Indicator | CW | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 68.97 | 29.43 |
| Support Level | $641.55 | $265.78 |
| Resistance Level | $667.82 | $288.98 |
| Average True Range (ATR) | 19.31 | 8.60 |
| MACD | 2.22 | -1.15 |
| Stochastic Oscillator | 89.38 | 0.11 |
Curtiss-Wright Corporation delivers engineered products and services to commercial, defence, power generation, and other industrial markets. It offers industrial vehicle components, control systems, weapons handling systems, pumps, valves, and other solutions. The company has three reportable segments based on the markets serviced: Naval & Power, which provides coolant pumps, power-dense compact motors, generators, secondary propulsion systems, pumps, pump seals, valves, control rod drive mechanisms, and fastening systems that also generate maximum revenue for the company; Its others segments are Aerospace & Industrial and Defense Electronics. Geographically, the company generates its key revenue from the United States of America, followed by the United Kingdom and other countries.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.